University of Dundee

100 years of suramin

Wiedemar, Natalie; Hauser, Dennis A.; Mäser, Pascal

Published in:
Antimicrobial Agents and Chemotherapy

DOI:
[10.1128/AAC.01168-19](https://doi.org/10.1128/AAC.01168-19)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Wiedemar, N., Hauser, D. A., & Mäser, P. (2020). 100 years of suramin. *Antimicrobial Agents and Chemotherapy*, 64(3), 1-14. [e01168]. <https://doi.org/10.1128/AAC.01168-19>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

- 1 **One Hundred Years of Suramin**
2
3
4 Natalie Wiedemar^{1,2}, Dennis A. Hauser^{1,2} and Pascal Mäser^{1,2}
5
6
7 ¹ Swiss Tropical and Public Health Institute
8 Dept. Medical Parasitology and Infection Biology
9 Socinstrasse 57
10 4051 Basel
11 Switzerland
12
13 ² University of Basel
14 Petersplatz 1
15 4001 Basel
16 Switzerland

17 **Abstract**

18 Suramin is a hundred years old and still being used to treat the first stage of acute human sleeping
19 sickness, caused by *Trypanosoma brucei rhodesiense*. Suramin is a multifunctional molecule with a
20 wide array of potential applications, from parasitic and viral diseases to cancer, snakebite and
21 autism. Suramin is also an enigmatic molecule: What are its targets? And how does it get into cells
22 in the first place? Here we provide an overview on the many different candidate targets of suramin,
23 discuss modes of action, and routes of cellular uptake. We reason that once the polypharmacology
24 of suramin is understood at the molecular level, new, more specific, and less toxic molecules can be
25 identified for the numerous potential applications of suramin.

26 *Suramin, the fruit of early medicinal chemistry*

27 When suramin was introduced for the treatment of African sleeping sickness in 1922, it was one of
28 the first anti-infective agents that had been developed in a medicinal chemistry program. Starting
29 from the antitrypanosomal activity of the dye trypan blue, synthesized in 1904 by Paul Ehrlich,
30 Bayer made a series of colorless and more potent derivatives. Molecule 205 was suramin (Figure 1),
31 synthesized by Oskar Dressel, Richard Kothe and Bernhard Heymann in 1916. Sleeping sickness
32 (also known as human African trypanosomiasis, HAT) was at the forefront of research at that time,
33 not a neglected disease as it is today, and the development of suramin was a breakthrough for the
34 emerging field of chemotherapy. While the history of suramin has been reviewed elsewhere (1), we
35 focus here on the many potential applications of suramin and its enigmatic mode of action.

36

37 *Suramin as an antiparasitic drug*

38 Suramin is still being used for the treatment of *Trypanosoma brucei rhodesiense* infections (2).
39 However, it does not cross the blood-brain barrier and therefore is administered only for the first,
40 hemolymphatic stage of sleeping sickness, when the trypanosomes have not yet invaded the
41 patient's CNS. The standard treatment regimen for suramin is an initial test dose of 4-5 mg/kg
42 followed by five weekly doses of 20 mg/kg (but not more than 1 g) injected i.v. (3). Suramin is also
43 used for Surra (mal de caderas), caused by *T. evansi*, in particular for the treatment of camels (4).
44 The treatment regimen is a single injection i.v. of 10 mg/kg suramin, i.e. about 6-10 g (4). *In vitro*,
45 suramin also has some activity against *T. cruzi* (5). However, it is not used for Chagas' disease, and
46 studies in mice even suggested that suramin would exacerbate the disease (6). *In vitro* activity of
47 suramin against *Leishmania major* and *L. donovani* has recently been described (7). Furthermore,
48 suramin blocks host cell invasion by the malaria parasite *Plasmodium falciparum*. This was
49 observed for both the invasion of erythrocytes by *P. falciparum* merozoites (8) and the invasion of
50 HepG2 hepatoma cells by *P. falciparum* sporozoites (9).

51 Suramin had been in use for river blindness, caused by the filarial parasite *Onchocerca*
52 *volvulus* (10). It acts on both microfilariae and, to a larger extent, on adult worms (11, 12).
53 However, suramin was subsequently replaced by the less toxic, and orally bioavailable, ivermectin
54 (13, 14). The adverse effects of suramin are indeed manifold, including nephrotoxicity,
55 hypersensitivity reactions, dermatitis, anemia, peripheral neuropathy and bone marrow toxicity (3,
56 15). But despite its potential toxicity, the lack of bioavailability, and absence of lead-like properties
57 (Figure 1), suramin has found a surprising variety of repurposing applications. Table 1 provides an
58 overview on the biological activities of suramin and Table 2 lists clinical trials performed with
59 suramin.

60

61 *Suramin as an antiviral agent*

62 The antiviral and antibacteriophage activities of suramin are known since the mid-20th century (19,
63 20). Soon after the discovery of retroviruses, suramin was found to inhibit retroviral reverse
64 transcriptase (21), which served as a rationale to test suramin against human immunodeficiency
65 virus (HIV). Suramin protected T-cells from HIV infection *in vitro* (22), and in AIDS patients it
66 reduced the viral burden in some of the study subjects; however, no improvement of the
67 immunological features and clinical symptoms was achieved (17, 23, 24). Later-on suramin was
68 found to inhibit host cell attachment through binding to the HIV-1 envelope glycoprotein gp120,
69 indicating that the *in vitro* protection against HIV infection is mediated through inhibition of viral
70 entry (25).

71 Suramin also inhibits the binding of Dengue virus to host cells through a direct effect on the
72 viral envelope protein (26). Inhibition of host cell attachment was also found for Herpes
73 simplex (27) and Hepatitis C viruses (28), which explained the previously reported protective
74 effects of suramin against *in vitro* herpes simplex infections (29) and *in vivo* infections of ducks
75 with Duck Hepatitis B Virus (30). Similar to the experience with HIV, suramin had initially been

76 tested against Hepatitis viruses due to its inhibitory effect on the viral DNA polymerase (31, 32).
77 But in a small clinical trial suramin was found to be ineffective and toxic in chronic active Hepatitis
78 B patients (18). Suramin neutralized enterovirus 71 (EV71) in cell culture and in a mouse model by
79 binding to capsid proteins (33–35).

80 Suramin also bears potential against emerging viruses. It was shown to inhibit both RNA
81 synthesis and replication in Chikungunya virus (36). *In vitro* suramin conferred protection if present
82 at the time of infection, and this was attributed to a reduction of viral host cell binding and
83 uptake (37). In the murine model suramin led to a reduction of pathognomonic lesions if injected
84 prior to Chikungunya infection (38). Suramin also inhibited host cell invasion by Ebola virus (39)
85 and Zika virus, even when added after viral exposure of the cell cultures (40).

86

87 *Suramin against cancer*

88 The first studies on the effects of suramin on neoplasms in animals were carried out in the 1940's;
89 mice engrafted with lymphosarcoma developed significantly smaller tumors when simultaneously
90 treated with suramin (41). In the 1970's it was shown that suramin can enhance the action of
91 cyclophosphamide and adriamycin in mice engrafted with Ehrlich carcinoma (42). A first clinical
92 trial with suramin was carried out in the 1980's in advanced-stage adrenal and renal cancer
93 patients (16). Around half of the patients showed either partial or minimal responses, none showed
94 complete remission. Nevertheless, a number of subsequent clinical trials with suramin were carried
95 out (Table 2). In particular, suramin was tested against prostate cancer (43–51), non-small cell lung
96 cancer (52), breast cancer (52), bladder cancer (53, 54) and brain tumors (55, 56). Most of these
97 studies were based on the potential of suramin to act as an antagonist of growth factors (57–59),
98 which are often overexpressed by tumors. In addition, suramin directly exhibits cytostatic activity
99 on cultured tumor cells (60–62). However, the initial clinical tests did not warrant the further
100 development of suramin as an anticancer monotherapy.

101 Subsequent tests focused on suramin as a chemosensitizer, based on the findings that at sub-
102 cytotoxic levels ($<50\ \mu\text{M}$), it enhanced the efficacy of anticancer drugs such as mitomycin C, taxol
103 or doxorubicin in *ex vivo* cultures and in animal models (63–65). Suramin combined with taxol
104 inhibited invasiveness and prevented metastasis in a xenograft mouse model (66). Different
105 explanations are conceivable for the chemosensitizing effects of suramin on tumor cells, including
106 inhibition of telomerase (67) or inhibition of fibroblast growth factors and angiogenesis (68). A
107 phase II clinical study was performed in patients with advanced, drug-resistant, non-small cell lung
108 cancer treated with taxol or carboplatin; supplementation with nontoxic doses of suramin did not
109 overcome drug resistance (69). Randomized controlled studies to validate the use of suramin as a
110 chemosensitizer in chemotherapy-naïve lung cancer patients remain to be performed. A
111 combination of estramustine, docetaxel and suramin gave promising results in hormone-refractory
112 prostate cancer patients (51).

113

114 *Suramin as an antidote*

115 Three of the many biological activities of suramin support a potential use as a protective agent: the
116 inhibition of thrombin, the inhibition of phospholipase A₂, and the inhibition of purinergic
117 signaling. Several vipers possess toxins that mimic thrombin (70), perfidiously triggering the
118 coagulation cascade in the mammalian blood. Suramin not only inhibits thrombin itself (71) but
119 also the thrombin-like proteases of snake venom (72), and was therefore proposed as an antidote for
120 snakebite. Other common constituents of metazoan venoms are phospholipases A₂ that convert
121 phospholipids into lysophospholipids. Again, suramin inhibits mammalian phospholipase A₂ (73)
122 as well as the orthologs from snake venom (74–76) and bee venom (77), suggesting that it can act
123 as an antidote. A certain degree of protection from venoms by suramin was confirmed in mouse
124 models (77–79). The potential use of suramin as an antidote is attractive given the high global
125 burden of snakebites (80) and the current shortage of antivenom (81).

126 Suramin's ability to block P2 purinergic, G protein-coupled receptors (82) may counteract
127 the action of neurotoxins that trigger arachidonic acid signaling, e.g. via phospholipase A2
128 activity (83). A possible explanation is that suramin prevents the activation of ATP receptors at the
129 motor nerve ending, which otherwise would depress Ca^{2+} currents and reduce acetylcholine release
130 at the presynaptic membrane (84). Suramin was also proposed to serve as a neuroprotective
131 agent (85, 86), as an antidote for kidney toxicity during cancer chemotherapy (87) and, based on its
132 antiapoptotic effect, to protect from liver failure (88). Suramin also inhibits connexin channels of
133 the tight junction, thereby suppressing ATP release and protecting cells from pore-forming bacterial
134 toxins such as hemolysin (89). The suramin analogs NF340 and NF546 were cardioprotective in a
135 mouse model for heart graft rejection, presumably via inhibition of the purinergic G protein-coupled
136 receptor P2Y11 (90).

137

138 *Further potential uses of suramin*

139 Suramin was found to have beneficial effects in a rat arthritis model (91) and to suppress fear
140 responses in the rat (92). It also promoted the expansion of T cells during immunization of mice and
141 was therefore considered as a small molecule adjuvant for vaccination (93). Based on the cell
142 danger hypothesis, suramin has recently been tested for the treatment of autism spectrum disorders
143 (ASD). The cell danger hypothesis suggests that a systemic stress response, which involves
144 mitochondria and purinergic signaling, contributes to the development of psychopathologies like
145 autism. Suramin had been shown to act as an inhibitor of purinergic signaling (94) and
146 mitochondrial function (95), and was therefore proposed as a potential therapy for ASD (96). First
147 tests in mouse models showed correction of symptoms in juveniles (96) as well as in adults (97). A
148 first small human trial was carried out and, even though difficult to quantify, showed improvement
149 of ASD symptoms (98).

150

151 *(Too) many targets*

152 Suramin is a large molecule that carries six negative charges at physiological pH (Figure 1). It is
153 likely to bind to, and thereby inhibit, various proteins (99). Thus the many and diverse potential
154 applications of suramin reflect the polypharmacology of suramin. Indeed, a large number of
155 enzymes have been shown to be inhibited by suramin (Table 3). Suramin inhibits many glycolytic
156 enzymes (100, 101), enzymes involved in galactose catabolism (PubChem BioAssay: 493189) and
157 enzymes of the Krebs cycle (102). Suramin further decreases the activity of a large number of
158 enzymes involved in DNA and RNA synthesis and modification: DNA polymerases (103, 104),
159 RNA polymerases (103, 105, 106), reverse transcriptase (21, 103), telomerase (67), and enzymes
160 involved in winding/unwinding of DNA (107, 108) are inhibited by suramin, as well as histone- and
161 chromatin modifying enzymes like chromobox proteins (109), methyltransferases (110) and sirtuin
162 histone deacetylases (111). Suramin is also an inhibitor of other sirtuins (112) and protein kinases
163 (113, 114), glutaminase (PubChem BioAssay: 624170), phospholipase A2 (115, 116), protein
164 tyrosine phosphatases (117), lysozyme (118) and different serine- and cysteine-proteases (119–
165 121). For caspases, cysteine proteases involved in apoptosis, suramin was described to act as either
166 inhibitor or activator (122, 123). Suramin further inhibits the Na^+, K^+ -ATPase and other ATPases
167 (124–126), certain classes of GABA receptors (127, 128), and several G protein-coupled
168 receptors (129) including P2 purinoceptors and follicle-stimulating hormone receptor (130, 131).
169 Suramin also showed inhibitory effects against components of the coagulation cascade (71, 132)
170 and the complement system (133–135), and against deubiquitinating enzymes (PubChem BioAssay:
171 504865; 463106). It also interacts with prion protein, inhibiting the conversion into the pathogenic
172 form PrP^{Sc} (136). Beside the many inhibitory activities, suramin also activates certain nuclear
173 receptors that act as transcription factors (137), and intracellular calcium channels (138).

174

175

176 *Enigmatic mechanisms of action against African trypanosomes*

177 Somewhat ironically, much less appears to be known about the targets of suramin in African
178 trypanosomes, where it has been in use for a century, than in tumor cells or viruses. Suramin was
179 shown to inhibit glycolytic enzymes of *T. brucei* with selectivity over their mammalian orthologues,
180 in particular hexokinase, aldolase, phosphoglycerate kinase and glycerol-3-phosphate
181 dehydrogenase (100). Intriguingly, the trypanosomal enzymes have higher isoelectric points (>9),
182 which is due to extra arginines and lysines that are absent in the mammalian orthologues (165).
183 These residues form positively charged, surface exposed 'hot spots' that were proposed to be bound
184 by the negatively charged suramin (100). Inhibition of trypanosomal glycolysis by suramin is in
185 agreement with the dose-dependent inhibition of oxygen consumption and ATP production
186 observed in trypanosomes isolated from suramin-treated rats (166). However, the glycolytic
187 enzymes of *T. brucei* are localized inside glycosomes (167), and it is unclear how suramin could
188 penetrate the glycosomal membrane, or if suramin could bind to glycolytic enzymes in the cytosol,
189 before they are imported into the glycosomes (168). Alternative targets proposed for the
190 trypanocidal effect of suramin are glycerophosphate oxidase (139, 169), a serine oligopeptidase
191 termed OP-Tb (170), and REL1 (171), the RNA-editing ligase of the trypanosome's kinetoplast. It is
192 unclear how suramin would pass the inner mitochondrial membrane, but suramin inhibited
193 oxidative phosphorylation in mitochondrial preparations of the trypanosomatid *Crithidia*
194 *fasciculata* (172). Suramin also appeared to inhibit cytokinesis in *T. brucei*, as indicated by the
195 finding that suramin treatment resulted in an increased number of trypanosomes with two
196 nuclei (173).

197

198 *Uptake routes of suramin into cells*

199 The negative charges of suramin (Figure 1) not only promote binding to various proteins, they also
200 prevent diffusion across biological membranes. However, the majority of targets (Table 3) are

201 intracellular, and radiolabeled suramin was shown to be taken up by human endothelial and
202 carcinoma cells (174, 175) and by *T. brucei* bloodstream forms (166, 176). Suramin is not a
203 substrate of P-glycoprotein (177), nor of any other known transporter. Thus suramin must be
204 imported by endocytosis. Mammalian cells can take up suramin in complex with serum albumin by
205 receptor-mediated endocytosis (178). This had originally also been thought to happen in *T.*
206 *brucei* (166). However, the trypanosomes do not take up albumin by receptor-mediated
207 endocytosis (179), and LDL (low density lipoprotein) was proposed to act as the vehicle
208 instead (176). Suramin bound to LDL and inhibited the binding and uptake of LDL, while LDL
209 enhanced the uptake of suramin in bloodstream-form *T. brucei* (176). In contrast, overexpression in
210 procyclic *T. b. brucei* of Rab4, a small GTPase involved in the recycling of endosomes, decreased
211 suramin binding and uptake without affecting LDL binding or uptake (180). In the same study,
212 overexpression of a mutant Rab5, which was locked in the active, GTP-bound form, increased LDL
213 uptake without affecting suramin uptake (180). These findings indicated that, at least in the
214 procyclic trypanosomes of the tsetse fly midgut, LDL and suramin are imported independently of
215 each other.

216 The development of genome-wide RNAi screens in bloodstream-form *T. brucei* combined
217 with next-generation sequencing offered new opportunities to address the genetics of drug
218 resistance. This approach identified genes, silencing of which reduced the sensitivity to
219 suramin (181). These included a number of genes encoding for endosomal and lysosomal proteins,
220 in agreement with uptake of suramin through endocytosis. The invariant surface glycoprotein
221 ISG75 was identified as a likely receptor of suramin since knock-down of ISG75 in bloodstream-
222 form *T. brucei* decreased suramin binding and suramin susceptibility (181). ISG75 is a surface
223 protein of unknown function whose abundance is controlled by ubiquitination (182). Thus, there
224 appear to be (at least) two pathways for receptor-mediated endocytosis of suramin in *T. brucei*

225 bloodstream forms: either directly with ISG75 as the receptor or, after binding of suramin to LDL,
226 together with the LDL receptor.

227

228 *Conclusion*

229 Suramin remains controversial. Is its polypharmacology a liability or an asset? Is it toxic or
230 protective? Dated or timeless? Whatever the verdict on suramin, there is hardly a molecule with as
231 many biological activities. The list of potential targets is indeed impressive, and the publication
232 stream on suramin is not stagnating. The large majority of papers is not about trypanosomes or
233 trypanosomiasis (Figure 2). The list of potential targets has to be taken with a grain of salt, though,
234 since the negative charges of suramin, and its promiscuity in protein binding, can cause all kinds of
235 artefacts. Suramin can dissolve matrigel (183), resulting in a false positive signal in cell-based
236 screening campaigns that use matrigel for support, e.g. for inhibitors of angiogenesis (183). On the
237 other hand, suramin's high affinity to albumin (184) may give false negative results in cell-based
238 tests that contain mammalian serum. But in spite of the various confounders, a number of different
239 drug-target interactions for suramin have been experimentally validated, and are directly supported
240 by crystal structures (Table 4).

241 Several routes of investigation on the bioactivities of suramin have culminated in clinical
242 trials with healthy volunteers (i.e. phase I) or patients (i.e. phases II and III; Table 2). Yet, to our
243 knowledge, none of these trials was a striking success, and it is unclear whether suramin will ever
244 find medical applications outside the field of parasitology. However, molecules that act in a similar
245 way than suramin may be identified via target-based screening once the mode of action is
246 understood – new molecules that are more specific, less toxic, and possess better pharmacological
247 properties than suramin. Thus it will be important to dissect the polypharmacology of suramin at the
248 molecular level. We hope that the compiled list of targets (Table 3) will serve this purpose.

249 **Acknowledgments**

250 We are grateful to the Swiss National Science Foundation for financial support and to Prof. Alan

251 Fairlamb for sharing insights into the possible molecular interactions of suramin.

252 **References**

- 253 1. Wainwright M. 2010. Dyes, trypanosomiasis and DNA: a historical and critical
254 review. *Biotech Histochem Off Publ Biol Stain Comm* 85:341–354.
- 255 2. Brun R, Blum J, Chappuis F, Burri C. 2010. Human African trypanosomiasis. *Lancet*
256 *Lond Engl* 375:148–159.
- 257 3. Burri C, Chappuis F, Brun R. 2014. Human African Trypanosomiasis, p. 606–691. *In*
258 *Manson's Tropical Diseases*, 23rd ed. Saunders Ltd.
- 259 4. Giordani F, Morrison LJ, Rowan TG, DE Koning HP, Barrett MP. 2016. The animal
260 trypanosomiasis and their chemotherapy: a review. *Parasitology* 143:1862–1889.
- 261 5. Bisaggio DFR, Adade CM, Souto-Padrón T. 2008. In vitro effects of suramin on
262 *Trypanosoma cruzi*. *Int J Antimicrob Agents* 31:282–286.
- 263 6. Santos EC, Novaes RD, Cupertino MC, Bastos DSS, Klein RC, Silva EAM, Fietto
264 JLR, Talvani A, Bahia MT, Oliveira LL. 2015. Concomitant Benznidazole and
265 Suramin Chemotherapy in Mice Infected with a Virulent Strain of *Trypanosoma*
266 *cruzi*. *Antimicrob Agents Chemother* 59:5999–6006.
- 267 7. Khanra S, Kumar YP, Dash J, Banerjee R. 2018. In vitro screening of known drugs
268 identified by scaffold hopping techniques shows promising leishmanicidal activity for
269 suramin and netilmicin. *BMC Res Notes* 11:319.
- 270 8. Fleck SL, Birdsall B, Babon J, Dluzewski AR, Martin SR, Morgan WD, Angov E,
271 Kettleborough CA, Feeney J, Blackman MJ, Holder AA. 2003. Suramin and suramin
272 analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte

- 273 invasion by the malaria parasite *Plasmodium falciparum*. *J Biol Chem* 278:47670–
274 47677.
- 275 9. Müller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A. 1993.
276 Thrombospondin related anonymous protein (TRAP) of *Plasmodium falciparum*
277 binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells
278 suggesting a role for this molecule in sporozoite invasion of hepatocytes. *EMBO J*
279 12:2881–2889.
- 280 10. Hawking F. 1958. Chemotherapy of onchocerciasis. *Trans R Soc Trop Med Hyg*
281 52:109–111.
- 282 11. Ashburn LL, Burch TA, Brady FJ. 1949. Pathologic effects of suramin, hetrazan and
283 arsenamide on adult *Onchocerca volvulus*. *Boletin Oficina Sanit Panam Pan Am*
284 *Sanit Bur* 28:1107–1117.
- 285 12. Burch TA, Ashburn LL. 1951. Experimental therapy of onchocerciasis with suramin
286 and hetrazan; results of a three-year study. *Am J Trop Med Hyg* 31:617–623.
- 287 13. Babalola OE. 2011. Ocular onchocerciasis: current management and future
288 prospects. *Clin Ophthalmol Auckl NZ* 5:1479–1491.
- 289 14. Coyne PE, Maxwell C. 1992. Suramin and therapy of onchocerciasis. *Arch Dermatol*
290 128:698.
- 291 15. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. 1993. Recent research on
292 the biological activity of suramin. *Pharmacol Rev* 45:177–203.

- 293 16. Stein CA, LaRocca RV, Thomas R, McAtee N, Myers CE. 1989. Suramin: an
294 anticancer drug with a unique mechanism of action. *J Clin Oncol Off J Am Soc Clin*
295 *Oncol* 7:499–508.
- 296 17. Kaplan LD, Wolfe PR, Volberding PA, Feorino P, Levy JA, Abrams DI, Kiprov D,
297 Wong R, Kaufman L, Gottlieb MS. 1987. Lack of response to suramin in patients
298 with AIDS and AIDS-related complex. *Am J Med* 82:615–620.
- 299 18. Loke RH, Anderson MG, Coleman JC, Tsiquaye KN, Zuckerman AJ, Murray-Lyon
300 IM. 1987. Suramin treatment for chronic active hepatitis B--toxic and ineffective. *J*
301 *Med Virol* 21:97–99.
- 302 19. Reiter B, Oram JD. 1962. Inhibition of streptococcal bacteriophage by suramin.
303 *Nature* 193:651–652.
- 304 20. Herrmann-Erlee MP, Wolff L. 1957. Inhibition of mumps virus reproduction by
305 congo red and suramine. *Arch Int Pharmacodyn Ther* 110:340–341.
- 306 21. De Clercq E. 1979. Suramin: a potent inhibitor of the reverse transcriptase of RNA
307 tumor viruses. *Cancer Lett* 8:9–22.
- 308 22. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. 1984.
309 Suramin protection of T cells in vitro against infectivity and cytopathic effect of
310 HTLV-III. *Science* 226:172–174.
- 311 23. Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, Klecker RW, Redfield
312 RR, Mitsuya H, Hoth DF, Gelmann E. 1985. Effects of suramin on HTLV-III/LAV
313 infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical

- 314 pharmacology and suppression of virus replication in vivo. *Lancet Lond Engl* 2:627–
315 630.
- 316 24. Cheson BD, Levine AM, Mildvan D, Kaplan LD, Wolfe P, Rios A, Groopman JE, Gill
317 P, Volberding PA, Poesz BJ. 1987. Suramin therapy in AIDS and related disorders.
318 Report of the US Suramin Working Group. *JAMA* 258:1347–1351.
- 319 25. Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalez-Scarano F, Fantini J. 1994.
320 Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to
321 galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. *J*
322 *Biol Chem* 269:24349–24353.
- 323 26. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM.
324 1997. Dengue virus infectivity depends on envelope protein binding to target cell
325 heparan sulfate. *Nat Med* 3:866–871.
- 326 27. Aguilar JS, Rice M, Wagner EK. 1999. The polysulfonated compound suramin
327 blocks adsorption and lateral diffusion of herpes simplex virus type-1 in vero cells.
328 *Virology* 258:141–151.
- 329 28. Garson JA, Lubach D, Passas J, Whitby K, Grant PR. 1999. Suramin blocks
330 hepatitis C binding to human hepatoma cells in vitro. *J Med Virol* 57:238–242.
- 331 29. Alarcón B, Lacal JC, Fernández-Sousa JM, Carrasco L. 1984. Screening for new
332 compounds with antiherpes activity. *Antiviral Res* 4:231–244.

- 333 30. Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. 1993. Suramin
334 prevents duck hepatitis B virus infection in vivo. *Antimicrob Agents Chemother*
335 37:1539–1542.
- 336 31. Tsiquaye K, Zuckerman A. 1985. Suramin inhibits duck hepatitis B virus DNA
337 polymerase activity. *J Hepatol* 1:663–669.
- 338 32. Tsiquaye KN, Collins P, Zuckerman AJ. 1986. Antiviral activity of the polybasic
339 anion, suramin and acyclovir in Hepadna virus infection. *J Antimicrob Chemother* 18
340 Suppl B:223–228.
- 341 33. Wang Y, Qing J, Sun Y, Rao Z. 2014. Suramin inhibits EV71 infection. *Antiviral Res*
342 103:1–6.
- 343 34. Ren P, Zou G, Bailly B, Xu S, Zeng M, Chen X, Shen L, Zhang Y, Guillon P,
344 Arenzana-Seisdedos F, Buchy P, Li J, von Itzstein M, Li Q, Altmeyer R. 2014. The
345 approved pediatric drug suramin identified as a clinical candidate for the treatment
346 of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. *Emerg*
347 *Microbes Infect* 3:e62.
- 348 35. Ren P, Zheng Y, Wang W, Hong L, Delpeyroux F, Arenzana-Seisdedos F, Altmeyer
349 R. 2017. Suramin interacts with the positively charged region surrounding the 5-fold
350 axis of the EV-A71 capsid and inhibits multiple enterovirus A. *Sci Rep* 7:42902.
- 351 36. Albulescu IC, van Hoolwerff M, Wolters LA, Bottaro E, Nastruzzi C, Yang SC, Tsay
352 S-C, Hwu JR, Snijder EJ, van Hemert MJ. 2015. Suramin inhibits chikungunya virus
353 replication through multiple mechanisms. *Antiviral Res* 121:39–46.

- 354 37. Ho Y-J, Wang Y-M, Lu J, Wu T-Y, Lin L-I, Kuo S-C, Lin C-C. 2015. Suramin Inhibits
355 Chikungunya Virus Entry and Transmission. *PloS One* 10:e0133511.
- 356 38. Kuo S-C, Wang Y-M, Ho Y-J, Chang T-Y, Lai Z-Z, Tsui P-Y, Wu T-Y, Lin C-C. 2016.
357 Suramin treatment reduces chikungunya pathogenesis in mice. *Antiviral Res*
358 134:89–96.
- 359 39. Henß L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, Becker S, Schnierle
360 BS. 2016. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
361 *Virol J* 13:149.
- 362 40. Tan CW, Sam I-C, Chong WL, Lee VS, Chan YF. 2017. Polysulfonate suramin
363 inhibits Zika virus infection. *Antiviral Res* 143:186–194.
- 364 41. Williams WL. 1946. The Effects of Suramin (Germanin), Azo Dyes, and Vasodilators
365 on Mice with Transplanted Lymphosarcomas. *AACR* 6:344–353.
- 366 42. Osswald H, Youssef M. 1979. Suramin enhancement of the chemotherapeutic
367 actions of cyclophosphamide or adriamycin of intramuscularly-implanted Ehrlich
368 carcinoma. *Cancer Lett* 6:337–343.
- 369 43. Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee
370 D, Reed E, Myers CE, Cooper MR. 1996. A phase I/II study of continuous infusion
371 suramin in patients with hormone-refractory prostate cancer: toxicity and response.
372 *Cancer Chemother Pharmacol* 39:1–8.
- 373 44. Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo
374 P, deKernion J, Belldegrun A. 1996. Suramin in hormone-refractory metastatic

- 375 prostate cancer: a drug with limited efficacy. *J Clin Oncol Off J Am Soc Clin Oncol*
376 14:1626–1636.
- 377 45. Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM,
378 Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. 1997.
379 Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic
380 prostate cancer. *J Clin Oncol Off J Am Soc Clin Oncol* 15:1470–1477.
- 381 46. Hussain M, Fisher EI, Petrylak DP, O'Connor J, Wood DP, Small EJ, Eisenberger
382 MA, Crawford ED. 2000. Androgen deprivation and four courses of fixed-schedule
383 suramin treatment in patients with newly diagnosed metastatic prostate cancer: A
384 Southwest Oncology Group Study. *J Clin Oncol Off J Am Soc Clin Oncol* 18:1043–
385 1049.
- 386 47. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF,
387 Chen L, Slichenmyer WJ, Eisenberger M. 2000. Suramin therapy for patients with
388 symptomatic hormone-refractory prostate cancer: results of a randomized phase III
389 trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. *J Clin*
390 *Oncol Off J Am Soc Clin Oncol* 18:1440–1450.
- 391 48. Calvo E, Cortés J, Rodríguez J, Sureda M, Beltrán C, Rebollo J, Martínez-Monge R,
392 Berián JM, de Irala J, Brugarolas A. 2001. Fixed higher dose schedule of suramin
393 plus hydrocortisone in patients with hormone refractory prostate carcinoma a
394 multicenter Phase II study. *Cancer* 92:2435–2443.
- 395 49. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago
396 R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. 2002. Randomized study of three

- 397 different doses of suramin administered with a fixed dosing schedule in patients with
398 advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B
399 9480. *J Clin Oncol Off J Am Soc Clin Oncol* 20:3369–3375.
- 400 50. Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T,
401 Giannone L, Arrieta R, Ratain MJ, Vokes EE. 2004. A Phase II trial of suramin
402 monthly x 3 for hormone-refractory prostate carcinoma. *Cancer* 100:65–71.
- 403 51. Safarinejad MR. 2005. Combination chemotherapy with docetaxel, estramustine and
404 suramin for hormone refractory prostate cancer. *Urol Oncol* 23:93–101.
- 405 52. Mirza MR, Jakobsen E, Pfeiffer P, Lindebjerg-Clasen B, Bergh J, Rose C. 1997.
406 Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel
407 phase II studies. *Acta Oncol Stockh Swed* 36:171–174.
- 408 53. Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers
409 MA, Banks RE, Roberts ISD, Harris AL. 2005. Phase I trial of intravesical Suramin in
410 recurrent superficial transitional cell bladder carcinoma. *Br J Cancer* 92:2140–2147.
- 411 54. Uchio EM, Linehan WM, Figg WD, Walther MM. 2003. A phase I study of
412 intravesical suramin for the treatment of superficial transitional cell carcinoma of the
413 bladder. *J Urol* 169:357–360.
- 414 55. Grossman SA, Phuphanich S, Lesser G, Rozental J, Grochow LB, Fisher J,
415 Piantadosi S, New Approaches to Brain Tumor Therapy CNS Consortium. 2001.
416 Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade
417 gliomas. *J Clin Oncol Off J Am Soc Clin Oncol* 19:3260–3266.

- 418 56. Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR,
419 NABTT CNS Consortium study. 2004. Suramin and radiotherapy in newly
420 diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. *Neuro-Oncol*
421 6:15–20.
- 422 57. Hosang M. 1985. Suramin binds to platelet-derived growth factor and inhibits its
423 biological activity. *J Cell Biochem* 29:265–273.
- 424 58. Coffey RJ, Leof EB, Shipley GD, Moses HL. 1987. Suramin inhibition of growth
425 factor receptor binding and mitogenicity in AKR-2B cells. *J Cell Physiol* 132:143–
426 148.
- 427 59. Pollak M, Richard M. 1990. Suramin blockade of insulinlike growth factor I-
428 stimulated proliferation of human osteosarcoma cells. *J Natl Cancer Inst* 82:1349–
429 1352.
- 430 60. Spigelman Z, Dowers A, Kennedy S, DiSorbo D, O'Brien M, Barr R, McCaffrey R.
431 1987. Antiproliferative effects of suramin on lymphoid cells. *Cancer Res* 47:4694–
432 4698.
- 433 61. Takano S, Gately S, Engelhard H, Tsanaclis AM, Brem S. 1994. Suramin inhibits
434 glioma cell proliferation in vitro and in the brain. *J Neurooncol* 21:189–201.
- 435 62. Guo XJ, Fantini J, Roubin R, Marvaldi J, Rougon G. 1990. Evaluation of the effect of
436 suramin on neural cell growth and N-CAM expression. *Cancer Res* 50:5164–5170.

- 437 63. Song S, Yu B, Wei Y, Wientjes MG, Au JL-S. 2004. Low-dose suramin enhanced
438 paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast
439 xenograft tumors. *Clin Cancer Res Off J Am Assoc Cancer Res* 10:6058–6065.
- 440 64. Xin Y, Lyness G, Chen D, Song S, Wientjes MG, Au JL-S. 2005. Low dose suramin
441 as a chemosensitizer of bladder cancer to mitomycin C. *J Urol* 174:322–327.
- 442 65. Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM, Au JLS, Wientjes MG.
443 2006. Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in
444 dogs with naturally occurring cancers. *J Vet Intern Med* 20:1172–1177.
- 445 66. Singla AK, Bondareva A, Jirik FR. 2014. Combined treatment with paclitaxel and
446 suramin prevents the development of metastasis by inhibiting metastatic
447 colonization of circulating tumor cells. *Clin Exp Metastasis* 31:705–714.
- 448 67. Gan Y, Lu J, Yeung BZ, Cottage CT, Wientjes MG, Au JL-S. 2015.
449 Pharmacodynamics of telomerase inhibition and telomere shortening by
450 noncytotoxic suramin. *AAPS J* 17:268–276.
- 451 68. Villalona-Calero MA, Wientjes MG, Otterson GA, Kanter S, Young D, Murgu AJ,
452 Fischer B, DeHoff C, Chen D, Yeh T-K, Song S, Grever M, Au JL-S. 2003. Phase I
453 study of low-dose suramin as a chemosensitizer in patients with advanced non-
454 small cell lung cancer. *Clin Cancer Res Off J Am Assoc Cancer Res* 9:3303–3311.
- 455 69. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D,
456 Murgu AJ, Jensen R, Yeh T-K, Wei Y, Zhang Y, Eng C, Grever M, Au JL-S. 2008.
457 Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell
458 lung cancer: a phase II study. *Ann Oncol Off J Eur Soc Med Oncol* 19:1903–1909.

- 459 70. Stocker K, Fischer H, Meier J. 1982. Thrombin-like snake venom proteinases.
460 Toxicon Off J Int Soc Toxinology 20:265–273.
- 461 71. Monteiro RQ, Campana PT, Melo PA, Bianconi ML. 2004. Suramin interaction with
462 human alpha-thrombin: inhibitory effects and binding studies. *Int J Biochem Cell Biol*
463 36:2077–2085.
- 464 72. Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Eliás S, Tomaz MA, Lomonte
465 B, Gutiérrez JM, Arni RK. 2005. Inhibition of myotoxic activity of *Bothrops asper*
466 myotoxin II by the anti-trypanosomal drug suramin. *J Mol Biol* 350:416–426.
- 467 73. Aragão EA, Vieira DS, Chioato L, Ferreira TL, Lourenzoni MR, Silva SR, Ward RJ.
468 2012. Characterization of suramin binding sites on the human group IIA secreted
469 phospholipase A2 by site-directed mutagenesis and molecular dynamics simulation.
470 *Arch Biochem Biophys* 519:17–22.
- 471 74. Salvador GHM, Dreyer TR, Cavalcante WLG, Matioli FF, Dos Santos JI, Velazquez-
472 Campoy A, Gallacci M, Fontes MRM. 2015. Structural and functional evidence for
473 membrane docking and disruption sites on phospholipase A2-like proteins revealed
474 by complexation with the inhibitor suramin. *Acta Crystallogr D Biol Crystallogr*
475 71:2066–2078.
- 476 75. Salvador GHM, Dreyer TR, Gomes AAS, Cavalcante WLG, Dos Santos JI, Gandin
477 CA, de Oliveira Neto M, Gallacci M, Fontes MRM. 2018. Structural and functional
478 characterization of suramin-bound MjTX-I from *Bothrops moojeni* suggests a
479 particular myotoxic mechanism. *Sci Rep* 8:10317.

- 480 76. Zhou X, Tan T-C, Valiyaveetil S, Go ML, Kini RM, Velazquez-Campoy A,
481 Sivaraman J. 2008. Structural characterization of myotoxic ecarpholin S from *Echis*
482 *carinatus* venom. *Biophys J* 95:3366–3380.
- 483 77. El-Kik CZ, Fernandes FFA, Tomaz MA, Gaban GA, Fonseca TF, Calil-Elias S,
484 Oliveira SDS, Silva CLM, Martinez AMB, Melo PA. 2013. Neutralization of *Apis*
485 *mellifera* bee venom activities by suramin. *Toxicon Off J Int Soc Toxinology* 67:55–
486 62.
- 487 78. Arruda EZ, Silva NMV, Moraes R a. M, Melo PA. 2002. Effect of suramin on
488 myotoxicity of some crotalid snake venoms. *Braz J Med Biol Res Rev Bras Pesqui*
489 *Medicas E Biol* 35:723–726.
- 490 79. Fathi B, Amani F, Jami-al-ahmadi A, Zare A. 2010. Antagonistic effect of suramin
491 against the venom of the Iranian snake *Echis carinatus* in mice. *Iranian J Vet Sci*
492 *Technol* 2:19–15.
- 493 80. The Lancet, Editorial. 2017. Snake-bite envenoming: a priority neglected tropical
494 disease. *Lancet Lond Engl* 390:2.
- 495 81. Arnold C. 2016. Vipers, mambas and taipans: the escalating health crisis over
496 snakebites. *Nature* 537:26–28.
- 497 82. den Hertog A, Nelemans A, Van den Akker J. 1989. The inhibitory action of suramin
498 on the P2-purinoceptor response in smooth muscle cells of guinea-pig taenia caeci.
499 *Eur J Pharmacol* 166:531–534.

- 500 83. Kuruppu S, Chaisakul J, Smith AI, Hodgson WC. 2014. Inhibition of presynaptic
501 neurotoxins in taipan venom by suramin. *Neurotox Res* 25:305–310.
- 502 84. Grishin S, Shakirzyanova A, Giniatullin A, Afzalov R, Giniatullin R. 2005.
503 Mechanisms of ATP action on motor nerve terminals at the frog neuromuscular
504 junction. *Eur J Neurosci* 21:1271–1279.
- 505 85. Ong WY, Motin LG, Hansen MA, Dias LS, Ayrout C, Bennett MR, Balcar VJ. 1997.
506 P2 purinoceptor blocker suramin antagonises NMDA receptors and protects against
507 excitatory behaviour caused by NMDA receptor agonist (RS)-(tetrazol-5-yl)-glycine
508 in rats. *J Neurosci Res* 49:627–638.
- 509 86. Kharlamov A, Jones SC, Kim DK. 2002. Suramin reduces infarct volume in a model
510 of focal brain ischemia in rats. *Exp Brain Res* 147:353–359.
- 511 87. Dupre TV, Doll MA, Shah PP, Sharp CN, Kiefer A, Scherzer MT, Saurabh K, Saforo
512 D, Siow D, Casson L, Arteel GE, Jenson AB, Megyesi J, Schnellmann RG, Beverly
513 LJ, Siskind LJ. 2016. Suramin protects from cisplatin-induced acute kidney injury.
514 *Am J Physiol Renal Physiol* 310:F248-258.
- 515 88. Doggrell SA. 2004. Suramin: potential in acute liver failure. *Expert Opin Investig*
516 *Drugs* 13:1361–1363.
- 517 89. Chi Y, Gao K, Zhang H, Takeda M, Yao J. 2014. Suppression of cell membrane
518 permeability by suramin: involvement of its inhibitory actions on connexin 43
519 hemichannels. *Br J Pharmacol* 171:3448–3462.

- 520 90. Bourguignon T, Benoist L, Chadet S, Miquelestreana-Standley E, Fromont G,
521 Ivanes F, Angoulvant D. 2019. Stimulation of murine P2Y11-like purinoreceptor
522 protects against hypoxia/reoxygenation injury and decreases heart graft rejection
523 lesions. *J Thorac Cardiovasc Surg* 158:780–790.e1.
- 524 91. Sahu D, Saroha A, Roy S, Das S, Srivastava PS, Das HR. 2012. Suramin
525 ameliorates collagen induced arthritis. *Int Immunopharmacol* 12:288–293.
- 526 92. Zou CJ, Onaka TO, Yagi K. 1998. Effects of suramin on neuroendocrine and
527 behavioural responses to conditioned fear stimuli. *Neuroreport* 9:997–999.
- 528 93. Denking M, Shive CL, Pantenburg B, Forsthuber TG. 2004. Suramin has adjuvant
529 properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo. *Int*
530 *Immunopharmacol* 4:15–24.
- 531 94. Dunn PM, Blakeley AG. 1988. Suramin: a reversible P2-purinoceptor antagonist in
532 the mouse vas deferens. *Br J Pharmacol* 93:243–245.
- 533 95. Bernardes CF, Fagian MM, Meyer-Fernandes JR, Castilho RF, Vercesi AE. 2001.
534 Suramin inhibits respiration and induces membrane permeability transition in
535 isolated rat liver mitochondria. *Toxicology* 169:17–23.
- 536 96. Naviaux RK, Zolkipli Z, Wang L, Nakayama T, Naviaux JC, Le TP, Schuchbauer
537 MA, Rogac M, Tang Q, Dugan LL, Powell SB. 2013. Antipurinergic therapy corrects
538 the autism-like features in the poly(IC) mouse model. *PLoS One* 8:e57380.

- 539 97. Naviaux JC, Schuchbauer MA, Li K, Wang L, Risbrough VB, Powell SB, Naviaux
540 RK. 2014. Reversal of autism-like behaviors and metabolism in adult mice with
541 single-dose antipurinergic therapy. *Transl Psychiatry* 4:e400.
- 542 98. Naviaux RK, Curtis B, Li K, Naviaux JC, Bright AT, Reiner GE, Westerfield M, Goh
543 S, Alaynick WA, Wang L, Capparelli EV, Adams C, Sun J, Jain S, He F, Arellano
544 DA, Mash LE, Chukoskie L, Lincoln A, Townsend J. 2017. Low-dose suramin in
545 autism spectrum disorder: a small, phase I/II, randomized clinical trial. *Ann Clin*
546 *Transl Neurol* 4:491–505.
- 547 99. Town BW, Wills ED, Wilson EJ, Wormall A. 1950. Studies on suramin; the action of
548 the drug on enzymes and some other proteins. General considerations. *Biochem J*
549 47:149–158.
- 550 100. Willson M, Callens M, Kuntz DA, Perié J, Oppendoes FR. 1993. Synthesis and
551 activity of inhibitors highly specific for the glycolytic enzymes from *Trypanosoma*
552 *brucei*. *Mol Biochem Parasitol* 59:201–210.
- 553 101. Morgan HP, McNae IW, Nowicki MW, Zhong W, Michels PAM, Auld DS, Fothergill-
554 Gilmore LA, Walkinshaw MD. 2011. The trypanocidal drug suramin and other trypan
555 blue mimetics are inhibitors of pyruvate kinases and bind to the adenosine site. *J*
556 *Biol Chem* 286:31232–31240.
- 557 102. Stoppani AO, Brignone JA. 1957. Inhibition of succinic dehydrogenase by
558 polysulfonated compounds. *Arch Biochem Biophys* 68:432–451.

- 559 103. Ono K, Nakane H, Fukushima M. 1988. Differential inhibition of various
560 deoxyribonucleic and ribonucleic acid polymerases by suramin. *Eur J Biochem*
561 172:349–353.
- 562 104. Jindal HK, Anderson CW, Davis RG, Vishwanatha JK. 1990. Suramin affects DNA
563 synthesis in HeLa cells by inhibition of DNA polymerases. *Cancer Res* 50:7754–
564 7757.
- 565 105. Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D, Robel I,
566 Rohayem J, Bolognesi M, Milani M. 2012. Structure-based inhibition of Norovirus
567 RNA-dependent RNA polymerases. *J Mol Biol* 419:198–210.
- 568 106. Waring MJ. 1965. The effects of antimicrobial agents on ribonucleic acid
569 polymerase. *Mol Pharmacol* 1:1–13.
- 570 107. Basavannacharya C, Vasudevan SG. 2014. Suramin inhibits helicase activity of
571 NS3 protein of dengue virus in a fluorescence-based high throughput assay format.
572 *Biochem Biophys Res Commun* 453:539–544.
- 573 108. Bojanowski K, Lelievre S, Markovits J, Couprie J, Jacquemin-Sablon A, Larsen AK.
574 1992. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese
575 hamster fibrosarcoma cells. *Proc Natl Acad Sci U S A* 89:3025–3029.
- 576 109. Ren C, Morohashi K, Plotnikov AN, Jakoncic J, Smith SG, Li J, Zeng L, Rodriguez
577 Y, Stojanoff V, Walsh M, Zhou M-M. 2015. Small-molecule modulators of methyl-
578 lysine binding for the CBX7 chromodomain. *Chem Biol* 22:161–168.

- 579 110. Feng Y, Li M, Wang B, Zheng YG. 2010. Discovery and mechanistic study of a class
580 of protein arginine methylation inhibitors. *J Med Chem* 53:6028–6039.
- 581 111. Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. 2007. Structure-
582 activity studies on suramin analogues as inhibitors of NAD⁺-dependent histone
583 deacetylases (sirtuins). *ChemMedChem* 2:1419–1431.
- 584 112. Schuetz A, Min J, Antoshenko T, Wang C-L, Allali-Hassani A, Dong A, Loppnau P,
585 Vedadi M, Bochkarev A, Sternglanz R, Plotnikov AN. 2007. Structural basis of
586 inhibition of the human NAD⁺-dependent deacetylase SIRT5 by suramin. *Struct*
587 *Lond Engl* 1993 15:377–389.
- 588 113. Hosoi Y, Matsumoto Y, Tomita M, Enomoto A, Morita A, Sakai K, Umeda N, Zhao
589 H-J, Nakagawa K, Ono T, Suzuki N. 2002. Phosphorothioate oligonucleotides,
590 suramin and heparin inhibit DNA-dependent protein kinase activity. *Br J Cancer*
591 86:1143–1149.
- 592 114. Hensey CE, Boscoboinik D, Azzi A. 1989. Suramin, an anti-cancer drug, inhibits
593 protein kinase C and induces differentiation in neuroblastoma cell clone NB2A.
594 *FEBS Lett* 258:156–158.
- 595 115. El-Kik CZ, Fernandes FFA, Tomaz MA, Gaban GA, Fonseca TF, Calil-Elias S,
596 Oliveira SDS, Silva CLM, Martinez AMB, Melo PA. 2013. Neutralization of Apis
597 mellifera bee venom activities by suramin. *Toxicon Off J Int Soc Toxinology* 67:55–
598 62.

- 599 116. Murakami MT, Arruda EZ, Melo PA, Martinez AB, Calil-Eliás S, Tomaz MA, Lomonte
600 B, Gutiérrez JM, Arni RK. 2005. Inhibition of myotoxic activity of *Bothrops asper*
601 myotoxin II by the anti-trypanosomal drug suramin. *J Mol Biol* 350:416–426.
- 602 117. Zhang YL, Keng YF, Zhao Y, Wu L, Zhang ZY. 1998. Suramin is an active site-
603 directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. *J*
604 *Biol Chem* 273:12281–12287.
- 605 118. Lominski I, Gray S. 1961. Inhibition of lysozyme by “Suramin.” *Nature* 192:683.
- 606 119. Vicik R, Hoerr V, Glaser M, Schultheis M, Hansell E, McKerrow JH, Holzgrabe U,
607 Caffrey CR, Ponte-Sucre A, Moll H, Stich A, Schirmeister T. 2006. Aziridine-2,3-
608 dicarboxylate inhibitors targeting the major cysteine protease of *Trypanosoma*
609 *brucei* as lead trypanocidal agents. *Bioorg Med Chem Lett* 16:2753–2757.
- 610 120. Cadène M, Durantón J, North A, Si-Tahar M, Chignard M, Bieth JG. 1997. Inhibition
611 of neutrophil serine proteinases by suramin. *J Biol Chem* 272:9950–9955.
- 612 121. Eisen V, Loveday C. 1973. Effects of suramin on complement, blood clotting,
613 fibrinolysis and kinin formation. *Br J Pharmacol* 49:678–687.
- 614 122. Eichhorst ST, Krueger A, Mürköster S, Fas SC, Golks A, Gruetzner U, Schubert L,
615 Opelz C, Bilzer M, Gerbes AL, Krammer PH. 2004. Suramin inhibits death receptor-
616 induced apoptosis in vitro and fulminant apoptotic liver damage in mice. *Nat Med*
617 10:602–609.

- 618 123. Tayel A, Ebrahim MA, Ibrahim AS, El-Gayar AM, Al-Gayyar MM. 2014. Cytotoxic
619 effects of suramin against HepG2 cells through activation of intrinsic apoptotic
620 pathway. J BUON Off J Balk Union Oncol 19:1048–1054.
- 621 124. Fortes PA, Ellory JC, Lew VL. 1973. Suramin: a potent ATPase inhibitor which acts
622 on the inside surface of the sodium pump. Biochim Biophys Acta 318:262–272.
- 623 125. Demenis MA, Furriel RPM, Leone FA. 2003. Characterization of an ectonucleoside
624 triphosphate diphosphohydrolase 1 activity in alkaline phosphatase-depleted rat
625 osseous plate membranes: possible functional involvement in the calcification
626 process. Biochim Biophys Acta 1646:216–225.
- 627 126. Magalhães L, de Oliveira AHC, de Souza Vasconcellos R, Mariotini-Moura C, de
628 Cássia Firmino R, Fietto JLR, Cardoso CL. 2016. Label-free assay based on
629 immobilized capillary enzyme reactor of *Leishmania infantum* nucleoside
630 triphosphate diphosphohydrolase (LicNTPDase-2-ICER-LC/UV). J Chromatogr B
631 Analyt Technol Biomed Life Sci 1008:98–107.
- 632 127. Luo H, Wood K, Shi F-D, Gao F, Chang Y. 2018. Suramin is a novel competitive
633 antagonist selective to $\alpha 1\beta 2\gamma 2$ GABAA over p1 GABAC receptors.
634 Neuropharmacology 141:148–157.
- 635 128. Nakazawa K, Inoue K, Ito K, Koizumi S, Inoue K. 1995. Inhibition by suramin and
636 reactive blue 2 of GABA and glutamate receptor channels in rat hippocampal
637 neurons. Naunyn Schmiedebergs Arch Pharmacol 351:202–208.

- 638 129. Chung W-C, Kermode JC. 2005. Suramin disrupts receptor-G protein coupling by
639 blocking association of G protein alpha and betagamma subunits. *J Pharmacol Exp*
640 *Ther* 313:191–198.
- 641 130. El-Ajouz S, Ray D, Allsopp RC, Evans RJ. 2012. Molecular basis of selective
642 antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of
643 basic amino acids in the cysteine-rich loop. *Br J Pharmacol* 165:390–400.
- 644 131. Stevis PE, Deecher DC, Lopez FJ, Frail DE. 1999. Pharmacological characterization
645 of soluble human FSH receptor extracellular domain: facilitated secretion by
646 coexpression with FSH. *Endocrine* 10:153–160.
- 647 132. La Rocca RV, Stein CA, Danesi R, Cooper MR, Uhrich M, Myers CE. 1991. A pilot
648 study of suramin in the treatment of metastatic renal cell carcinoma. *Cancer*
649 67:1509–1513.
- 650 133. Fong JS, Good RA. 1972. Suramin--a potent reversible and competitive inhibitor of
651 complement systems. *Clin Exp Immunol* 10:127–138.
- 652 134. Tsiftoglou SA, Sim RB. 2004. Human complement factor I does not require
653 cofactors for cleavage of synthetic substrates. *J Immunol Baltim Md* 1950 173:367–
654 375.
- 655 135. Tsiftoglou SA, Willis AC, Li P, Chen X, Mitchell DA, Rao Z, Sim RB. 2005. The
656 catalytically active serine protease domain of human complement factor I.
657 *Biochemistry (Mosc)* 44:6239–6249.

- 658 136. Nunziante M, Kehler C, Maas E, Kassack MU, Groschup M, Schätzl HM. 2005.
659 Charged bipolar suramin derivatives induce aggregation of the prion protein at the
660 cell surface and inhibit PrPSc replication. *J Cell Sci* 118:4959–4973.
- 661 137. Shukla SJ, Sakamuru S, Huang R, Moeller TA, Shinn P, Vanleer D, Auld DS, Austin
662 CP, Xia M. 2011. Identification of clinically used drugs that activate pregnane X
663 receptors. *Drug Metab Dispos Biol Fate Chem* 39:151–159.
- 664 138. Klinger M, Freissmuth M, Nickel P, Stäbler-Schwarzbart M, Kassack M, Suko J,
665 Hohenegger M. 1999. Suramin and suramin analogs activate skeletal muscle
666 ryanodine receptor via a calmodulin binding site. *Mol Pharmacol* 55:462–472.
- 667 139. Fairlamb AH, Bowman IB. 1977. Trypanosoma brucei: suramin and other
668 trypanocidal compounds' effects on sn-glycerol-3-phosphate oxidase. *Exp Parasitol*
669 43:353–361.
- 670 140. Dias DA, de Barros Penteadó B, Dos Santos LD, Dos Santos PM, Arruda CCP,
671 Schetinger MRC, Leal DBR, Dos Santos Jaques JA. 2017. Characterization of
672 ectonucleoside triphosphate diphosphohydrolase (E-NTPDase; EC 3.6.1.5) activity
673 in mouse peritoneal cavity cells. *Cell Biochem Funct* 35:358–363.
- 674 141. Oses JP, Cardoso CM, Germano RA, Kirst IB, Rücker B, Fürstenau CR, Wink MR,
675 Bonan CD, Battastini AMO, Sarkis JJF. 2004. Soluble NTPDase: An additional
676 system of nucleotide hydrolysis in rat blood serum. *Life Sci* 74:3275–3284.
- 677 142. Vasconcellos RDS, Mariotini-Moura C, Gomes RS, Serafim TD, Firmino R de C,
678 Silva E Bastos M, Castro FF de, Oliveira CM de, Borges-Pereira L, de Souza ACA,
679 de Souza RF, Gómez GAT, Pinheiro A da C, Maciel TEF, Silva-Júnior A, Bressan

- 680 GC, Almeida MR, Baqui MMA, Afonso LCC, Fietto JLR. 2014. Leishmania infantum
681 ecto-nucleoside triphosphate diphosphohydrolase-2 is an apyrase involved in
682 macrophage infection and expressed in infected dogs. PLoS Negl Trop Dis 8:e3309.
- 683 143. Santos RF, Pôssa MAS, Bastos MS, Guedes PMM, Almeida MR, Demarco R,
684 Verjovski-Almeida S, Bahia MT, Fietto JLR. 2009. Influence of Ecto-nucleoside
685 triphosphate diphosphohydrolase activity on Trypanosoma cruzi infectivity and
686 virulence. PLoS Negl Trop Dis 3:e387.
- 687 144. Iqbal J, Lévesque SA, Sévigny J, Müller CE. 2008. A highly sensitive CE-UV
688 method with dynamic coating of silica-fused capillaries for monitoring of nucleotide
689 pyrophosphatase/phosphodiesterase reactions. Electrophoresis 29:3685–3693.
- 690 145. Andréola ML, Tharaud D, Litvak S, Tarrago-Litvak L. 1993. The ribonuclease H
691 activity of HIV-1 reverse transcriptase: further biochemical characterization and
692 search of inhibitors. Biochimie 75:127–134.
- 693 146. Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez JJ,
694 Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN.
695 2012. Identification and analysis of hepatitis C virus NS3 helicase inhibitors using
696 nucleic acid binding assays. Nucleic Acids Res 40:8607–8621.
- 697 147. Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, Inglese J, Pommier Y,
698 Simeonov A. 2009. Identification of phosphotyrosine mimetic inhibitors of human
699 tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay.
700 Mol Cancer Ther 8:240–248.

- 701 148. Kakuguchi W, Nomura T, Kitamura T, Otsuguro S, Matsushita K, Sakaitani M,
702 Maenaka K, Tei K. 2018. Suramin, screened from an approved drug library, inhibits
703 HuR functions and attenuates malignant phenotype of oral cancer cells. *Cancer*
704 *Med* 7:6269–6280.
- 705 149. Paulson CN, John K, Baxley RM, Kurniawan F, Orellana K, Francis R, Soback A,
706 Eichman BF, Chazin WJ, Aihara H, Georg GI, Hawkinson JE, Bielinsky A-K. 2019.
707 The anti-parasitic agent suramin and several of its analogues are inhibitors of the
708 DNA binding protein Mcm10. *Open Biol* 9:190117.
- 709 150. Horiuchi KY, Eason MM, Ferry JJ, Planck JL, Walsh CP, Smith RF, Howitz KT, Ma
710 H. 2013. Assay development for histone methyltransferases. *Assay Drug Dev*
711 *Technol* 11:227–236.
- 712 151. Peinado RDS, Olivier DS, Eberle RJ, de Moraes FR, Amaral MS, Arni RK,
713 Coronado MA. 2019. Binding studies of a putative *C. pseudotuberculosis* target
714 protein from Vitamin B12 Metabolism. *Sci Rep* 9:6350.
- 715 152. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE,
716 Chung P, Kisielewski A, Zhang L-L, Scherer B, Sinclair DA. 2003. Small molecule
717 activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 425:191–
718 196.
- 719 153. Trueblood KE, Mohr S, Dubyak GR. 2011. Purinergic regulation of high-glucose-
720 induced caspase-1 activation in the rat retinal Müller cell line rMC-1. *Am J Physiol*
721 *Cell Physiol* 301:C1213-1223.

- 722 154. Stark S, Schuller A, Sifringer M, Gerstner B, Brehmer F, Weber S, Altmann R,
723 Obladen M, Buhner C, Felderhoff-Mueser U. 2008. Suramin induces and enhances
724 apoptosis in a model of hyperoxia-induced oligodendrocyte injury. *Neurotox Res*
725 13:197–207.
- 726 155. Marques AF, Esser D, Rosenthal PJ, Kassack MU, Lima LMTR. 2013. Falcipain-2
727 inhibition by suramin and suramin analogues. *Bioorg Med Chem* 21:3667–3673.
- 728 156. Beiler JM, Martin GJ. 1948. Inhibition of hyaluronidase action by derivatives of
729 hesperidin. *J Biol Chem* 174:31–35.
- 730 157. Constantopoulos G, Rees S, Cragg BG, Barranger JA, Brady RO. 1980.
731 Experimental animal model for mucopolysaccharidosis: suramin-induced
732 glycosaminoglycan and sphingolipid accumulation in the rat. *Proc Natl Acad Sci U S*
733 A 77:3700–3704.
- 734 158. Bachmann A, Russ U, Quast U. 1999. Potent inhibition of the CFTR chloride
735 channel by suramin. *Naunyn Schmiedebergs Arch Pharmacol* 360:473–476.
- 736 159. Peoples RW, Li C. 1998. Inhibition of NMDA-gated ion channels by the P2
737 purinoceptor antagonists suramin and reactive blue 2 in mouse hippocampal
738 neurones. *Br J Pharmacol* 124:400–408.
- 739 160. Sharma A, Yogavel M, Sharma A. 2016. Structural and functional attributes of
740 malaria parasite diadenosine tetraphosphate hydrolase. *Sci Rep* 6:19981.

- 741 161. Vieira DS, Aragão EA, Lourenzoni MR, Ward RJ. 2009. Mapping of suramin binding
742 sites on the group IIA human secreted phospholipase A2. *Bioorganic Chem* 37:41–
743 45.
- 744 162. Quemé-Peña M, Juhász T, Mihály J, Cs Szigyártó I, Horváti K, Bősze S, Henczkó J,
745 Pályi B, Németh C, Varga Z, Zsila F, Beke-Somfai T. 2019. Manipulating Active
746 Structure and Function of Cationic Antimicrobial Peptide CM15 with the
747 Polysulfonated Drug Suramin: A Step Closer to in Vivo Complexity. *Chembiochem*
748 *Eur J Chem Biol*.
- 749 163. Abdeen S, Salim N, Mammadova N, Summers CM, Goldsmith-Pestana K,
750 McMahon-Pratt D, Schultz PG, Horwich AL, Chapman E, Johnson SM. 2016.
751 Targeting the HSP60/10 chaperonin systems of *Trypanosoma brucei* as a strategy
752 for treating African sleeping sickness. *Bioorg Med Chem Lett* 26:5247–5253.
- 753 164. Stevens M, Abdeen S, Salim N, Ray A-M, Washburn A, Chitre S, Sivinski J, Park Y,
754 Hoang QQ, Chapman E, Johnson SM. 2019. HSP60/10 chaperonin systems are
755 inhibited by a variety of approved drugs, natural products, and known bioactive
756 molecules. *Bioorg Med Chem Lett* 29:1106–1112.
- 757 165. Wierenga RK, Swinkels B, Michels PA, Osinga K, Misset O, Van Beeumen J,
758 Gibson WC, Postma JP, Borst P, Opperdoes FR. 1987. Common elements on the
759 surface of glycolytic enzymes from *Trypanosoma brucei* may serve as topogenic
760 signals for import into glycosomes. *EMBO J* 6:215–221.

- 761 166. Fairlamb AH, Bowman IB. 1980. Uptake of the trypanocidal drug suramin by
762 bloodstream forms of *Trypanosoma brucei* and its effect on respiration and growth
763 rate in vivo. *Mol Biochem Parasitol* 1:315–333.
- 764 167. Opperdoes FR, Borst P. 1977. Localization of nine glycolytic enzymes in a
765 microbody-like organelle in *Trypanosoma brucei*: the glycosome. *FEBS Lett* 80:360–
766 364.
- 767 168. Wang CC. 1995. Molecular mechanisms and therapeutic approaches to the
768 treatment of African trypanosomiasis. *Annu Rev Pharmacol Toxicol* 35:93–127.
- 769 169. Fairlamb A. 1975. A study of glycerophosphate oxidase in *Trypanosoma brucei*.
770 Ph.D. Thesis, University of Edinburgh.
- 771 170. Morty RE, Troeberg L, Pike RN, Jones R, Nickel P, Lonsdale-Eccles JD, Coetzer
772 TH. 1998. A trypanosome oligopeptidase as a target for the trypanocidal agents
773 pentamidine, diminazene and suramin. *FEBS Lett* 433:251–256.
- 774 171. Zimmermann S, Hall L, Riley S, Sørensen J, Amaro RE, Schnauffer A. 2016. A novel
775 high-throughput activity assay for the *Trypanosoma brucei* editosome enzyme REL1
776 and other RNA ligases. *Nucleic Acids Res* 44:e24.
- 777 172. Roveri OA, Franke de Cazzulo BM, Cazzulo JJ. 1982. Inhibition by suramin of
778 oxidative phosphorylation in *Crithidia fasciculata*. *Comp Biochem Physiol B* 71:611–
779 616.

- 780 173. Thomas JA, Baker N, Hutchinson S, Dominicus C, Trenaman A, Glover L, Alsford S,
781 Horn D. 2018. Insights into antitrypanosomal drug mode-of-action from cytology-
782 based profiling. *PLoS Negl Trop Dis* 12:e0006980.
- 783 174. Gagliardi AR, Taylor MF, Collins DC. 1998. Uptake of suramin by human
784 microvascular endothelial cells. *Cancer Lett* 125:97–102.
- 785 175. Baghdiguan S, Boudier JL, Boudier JA, Fantini J. 1996. Intracellular localisation of
786 suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by
787 quantitative autoradiography. *Eur J Cancer Oxf Engl* 1990 32A:525–532.
- 788 176. Vansterkenburg EL, Coppens I, Wilting J, Bos OJ, Fischer MJ, Janssen LH,
789 Opperdoes FR. 1993. The uptake of the trypanocidal drug suramin in combination
790 with low-density lipoproteins by *Trypanosoma brucei* and its possible mode of
791 action. *Acta Trop* 54:237–250.
- 792 177. Sanderson L, Khan A, Thomas S. 2007. Distribution of suramin, an
793 antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid
794 interfaces in wild-type and P-glycoprotein transporter-deficient mice. *Antimicrob*
795 *Agents Chemother* 51:3136–3146.
- 796 178. Baghdiguan S, Boudier JL, Boudier JA, Fantini J. 1996. Intracellular localisation of
797 suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by
798 quantitative autoradiography. *Eur J Cancer Oxf Engl* 1990 32A:525–532.
- 799 179. Coppens I, Opperdoes FR, Courtoy PJ, Baudhuin P. 1987. Receptor-mediated
800 endocytosis in the bloodstream form of *Trypanosoma brucei*. *J Protozool* 34:465–
801 473.

- 802 180. Pal A, Hall BS, Field MC. 2002. Evidence for a non-LDL-mediated entry route for the
803 trypanocidal drug suramin in *Trypanosoma brucei*. *Mol Biochem Parasitol* 122:217–
804 221.
- 805 181. Alsford S, Eckert S, Baker N, Glover L, Sanchez-Flores A, Leung KF, Turner DJ,
806 Field MC, Berriman M, Horn D. 2012. High-throughput decoding of antitrypanosomal
807 drug efficacy and resistance. *Nature* 482:232–236.
- 808 182. Zoltner M, Leung KF, Alsford S, Horn D, Field MC. 2015. Modulation of the Surface
809 Proteome through Multiple Ubiquitylation Pathways in African Trypanosomes. *PLoS*
810 *Pathog* 11:e1005236.
- 811 183. Prigozhina NL, Heisel AJ, Seldeen JR, Cosford NDP, Price JH. 2013. Amphiphilic
812 suramin dissolves Matrigel, causing an “inhibition” artefact within in vitro
813 angiogenesis assays. *Int J Exp Pathol* 94:412–417.
- 814 184. Vansterkenburg EL, Wilting J, Janssen LH. 1989. Influence of pH on the binding of
815 suramin to human serum albumin. *Biochem Pharmacol* 38:3029–3035.
- 816 185. Lozano RM, Jiménez M, Santoro J, Rico M, Giménez-Gallego G. 1998. Solution
817 structure of acidic fibroblast growth factor bound to 1,3, 6-naphthalenetrisulfonate: a
818 minimal model for the anti-tumoral action of suramins and suradistas. *J Mol Biol*
819 281:899–915.
- 820 186. Huang H-W, Mohan SK, Yu C. 2010. The NMR solution structure of human
821 epidermal growth factor (hEGF) at physiological pH and its interactions with
822 suramin. *Biochem Biophys Res Commun* 402:705–710.

- 823 187. Lima LMTR, Becker CF, Giesel GM, Marques AF, Cargnelutti MT, de Oliveira Neto
824 M, Monteiro RQ, Verli H, Polikarpov I. 2009. Structural and thermodynamic analysis
825 of thrombin:suramin interaction in solution and crystal phases. *Biochim Biophys*
826 *Acta* 1794:873–881.
- 827 188. Jiao L, Ouyang S, Liang M, Niu F, Shaw N, Wu W, Ding W, Jin C, Peng Y, Zhu Y,
828 Zhang F, Wang T, Li C, Zuo X, Luan C-H, Li D, Liu Z-J. 2013. Structure of severe
829 fever with thrombocytopenia syndrome virus nucleocapsid protein in complex with
830 suramin reveals therapeutic potential. *J Virol* 87:6829–6839.

831

832

833 TABLES

834

835 **Table 1.** Diseases and pathogens susceptible to suramin.

836

Disease, pathogen	Activity in cell culture	Activity in animal model	Activity in patient
Parasitic infections			
<i>T. b. rhodesiense</i> HAT	x	x	x
<i>T. b. gambiense</i> HAT	x	x	x
Surra, <i>T. evansi</i>	x	x	n.a.
River blindness, <i>O. volvulus</i>	x	x	x
<i>Trypanosoma cruzi</i>	x		
<i>Leishmania</i> spp.	x		
<i>Plasmodium falciparum</i>	x		
Viral infections			
Hepatitis	x	x	x
AIDS, HIV	x		x
Herpes simplex	x	x	
Chikungunya	x	x	
Enterovirus 71	x	x	
Dengue	x		
Zika	x		
Ebola	x		
Neoplastic diseases			
Non-small cell lung cancer	x	x	
Breast cancer	x	x	
Bladder cancer	x	x	
Brain tumors	x	x	
Prostate cancer	x	x	x
Other uses			
Snake bite	x	x	
Arthritis	x	x	
Autism	n.a.	x	x

837

838

839 **Table 2.** Clinical trials with suramin. Trials with a registered NCT number are from
 840 ClinicalTrials.gov; others are from the literature.

841

Registry ID	Disease	Phase	Year
NCT02508259	Autism spectrum disorders	I, II	2015
NCT01671332	Non-small cell lung cancer	II	2012
NCT01038752	Non-small cell lung cancer	II	2010
NCT00083109	Recurrent renal cell carcinoma	I, II	2004
NCT00066768	Recurrent non-small cell lung cancer	I	2003
NCT00054028	Recurrent breast cancer	I, II	2002
NCT00006929	Recurrent non-small cell lung cancer	II	2000
NCT00006476	Bladder cancer	I	2000
NCT00004073	Brain and central nervous system tumors	II	1999
NCT00002921	Adrenocortical carcinoma	II	1997
NCT00003038	Advanced solid tumors	I	1997
NCT00002723	Prostate cancer	III	1996
NCT00002881	Prostate cancer	III	1996
NCT00002652	Multiple myeloma and plasma cell neoplasm	II	1995
NCT00002639	Brain and central nervous system tumors	II	1995
NCT00001381	Bladder neoplasms, transitional cell carcinoma	I	1994
NCT00001266	Prostatic neoplasm	II	1990
NCT00001230	Filariasis	observ.	1988
(16)	Solid tumors	observ.	1987
(17)	AIDS	observ.	1987
(18)	Hepatitis B	observ.	1987

842

843

844 **Table 3.** Putative target proteins of suramin, biological processes and mechanisms. Suramin acts as
 845 an inhibitor or antagonist in all cases except for the pregnane X receptor and the ryanodine receptor.
 846 The mode of action against caspase is controversial.
 847

Putative target	Reference
Metabolism	
6-Phosphofructokinase	(100)
Fructose-1,6-bisphosphate aldolase	(100)
Glucose-6-phosphate isomerase	(100)
Glyceraldehyde-3-phosphate dehydrogenase	(100)
Glycerol-3-phosphate dehydrogenase	(100, 139)
Glycerol kinase	(100)
Hexokinase	(100)
Phosphoglycerate kinase	(100)
Pyruvate kinase	(101)
Triose-phosphate isomerase	(100)
Succinic dehydrogenase	(102)
Galactokinase	493189*
Glutaminase	624170*
Glycerophosphate oxidase	(139)
Nucleoside triphosphate diphosphohydrolase 1 & 2	(125, 126, 140–143)
Nucleotide pyrophosphatase/phosphodiesterase 1 & 3	(144)
Nucleic acids	
DNA polymerase alpha	(103, 104)
DNA polymerase beta	(103, 104)
DNA polymerase gamma	(103)
DNA polymerase delta	(104)
DNA polymerase I	(103, 104)
Terminal deoxynucleotidyltransferase	(103)
DNA primase	(103)
DNA dependent RNA polymerase	(103, 106)
RNA dependent RNA polymerase	(105)
Reverse transcriptase	(21, 103)
Telomerase	(67)
RNAse H	(145)
Flavivirus RNA helicase	(40, 107, 146)
DNA Topoisomerase II	(108)
Tyrosyl-DNA phosphodiesterase 1	(147)
Human antigen R	(148)
DNA-binding protein MCM10	(149)
Epigenetics	
Chromobox protein homologue 1 beta	488953*
Chromobox protein homologue 7	(109)
Histone methyltransferases	(110, 150)
Precorrin-4 C(11)-methyltransferase	(151)
Sirtuin 1, 2, 5	(111, 112, 152)

Protease

Kallikrein	(121)
Alpha Thrombin	(71)
Human neutrophil cathepsin G	(120)
Human neutrophil elastase	(120)
Human neutrophil proteinase 3	(120)
Rhodesain	(119)
Caspases 1, 2, 8, 9, 10	(122, 123, 153, 154)
Falcpain-2	(155)

Extracellular matrix

Hyaluronidase	(156, 157)
Iduronate sulfatase	(157)
β -glucuronidase	(157)

Membrane channels and signaling

Non-junctional connexin 43 hemichannels	(89)
Na^+, K^+ -ATPase	(124)
Cystic fibrosis transmembrane regulator	(158)
Ryanodine receptor 1	(138)
GABA _A receptors	(127, 128)
P2X Purinergic receptors	(94)
P2Y Purinergic receptors	(94)
N-methyl-D-aspartate receptor	(159)
DNA-dependent protein kinase	(113)
Protein kinase C	(114)
Protein tyrosine phosphatases	(117)
VIP receptor	(129)
Follicle-stimulating hormone receptor	(131)
Pregnane X receptor	(137)
Diadenosine tetraphosphate hydrolase	(160)

Other

Prion (Prp ^C)	(136)
Complement factors	(121, 133–135)
Phospholipase A ₂	(116, 161)
Lysozyme	(118)
Antimicrobial Peptide CM15	(162)
Ubiquitin carboxyl-terminal hydrolases 1 & 2	504865; 463106*
HSP 60 chaperonin system	(163, 164)
GroEL chaperonin system	(163, 164)

848 *PubChem BioAssay, last retrieved 29.04.2019

849

850 **Table 4.** Solved structures of suramin complexed to target proteins.

851

PDB id	Protein	Reference
6CE2	Myotoxin I from <i>Bothrops moojeni</i>	(75)
4YV5	Myotoxin II from <i>Bothrops moojeni</i>	(74)
1Y4L	Myotoxin II from <i>Bothrops asper</i>	(116)
3BJW	Ecarpholin S from <i>Echis carinatus</i>	(76)
1RML	Acid fibroblast growth factor	(185)
n.a.	Human epidermal growth factor (hEGF)	(186)
4X3U	CBX7 chromodomain	(109)
3BF6, 2H9T	Human thrombin	(187)
2NYR	Human sirtuin homolog 5	(112)
3PP7	<i>Leishmania mexicana</i> pyruvate kinase	(101)
3GAN	<i>Arabidopsis thaliana</i> At3g22680	n.a.
3UR0	Murine norovirus RNA-dependent RNA polymerase	(105)
4J4V	Pentameric bunyavirus nucleocapsid protein	(188)
4J4R	Hexameric bunyavirus nucleocapsid protein	(188)

852

853

854 FIGURE LEGENDS

855

856 **Figure 1.** Suramin structure and medicinal chemistry parameters. Except for its good solubility in
857 water, suramin lacks lead-like properties as defined e.g. by Lipinsky's rule of 5.

858

859 **Figure 2.** Publications on suramin in PubMed. Cumulative numbers are shown for papers on
860 suramin and trypanosomes or trypanosomiasis (black, search term "trypanosom*"), cancer (red,
861 "cancer OR tumor"), viruses (yellow, "virus OR viral OR hiv OR aids"), and toxins (green, "toxin
862 OR venom"). Other papers on suramin are shown in beige. There is no saturation yet. And it is
863 surprising that only a minority of the publications on suramin actually deal with trypanosomes.

Molecular weight	1297 Da
H-bond donors	12
H-bond acceptors	23
logP	0.00023
Protein binding	99.7%
Metabolites	none
Biological half-life	44-54 days
Metabolites	none
Elimination pathway	urinary

Number of publications

- trypanosomes
- cancer
- viruses
- toxins
- other

1960 1980 2000 2018